Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1856)
All Articles published online
|
Jul 14, 2007 (publication date) through Apr 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Drescher D, Moehler M, Gockel I, Frerichs K, Müller A, Dünschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR, Schimanski CC. Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol 2007; 13(26): 3605-3609 [PMID: 17659711 DOI: 10.3748/wjg.v13.i26.3605] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i26/3605.htm |
| Number | Citing Articles |
| 1 |
Kensei Yamaguchi, Nozomu Fuse, Yoshito Komatsu, Hirofumi Fujii, Shuichi Hironaka, Yasushi Omuro, Kei Muro, Hirofumi Yasui, Shinya Ueda, Tomohiro Nishina, Morihiro Watanabe, Atsushi Ohtsu. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. Japanese Journal of Clinical Oncology 2021; 51(6): 879 doi: 10.1093/jjco/hyaa276
|
| 2 |
Anna Choromańska, Agnieszka Chwiłkowska, Julita Kulbacka, Dagmara Baczyńska, Nina Rembiałkowska, Anna Szewczyk, Olga Michel, Agnieszka Gajewska-Naryniecka, Dawid Przystupski, Jolanta Saczko. Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy. Molecules 2021; 26(7): 1850 doi: 10.3390/molecules26071850
|
| 3 |
Izuma Nakayama, Daisuke Takahari. The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review. Journal of Clinical Medicine 2023; 12(9): 3226 doi: 10.3390/jcm12093226
|
| 4 |
Shioto Suzuki, Yoh Dobashi, Yayoi Hatakeyama, Ryosuke Tajiri, Takashi Fujimura, Carl H Heldin, Akishi Ooi. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer. BMC Cancer 2010; 10(1) doi: 10.1186/1471-2407-10-659
|
| 5 |
Orestis Lyros, Annett Mueller, Florian Heidel, Carl C. Schimanski, Ines Gockel, Peter R. Galle, Hauke Lang, Markus Moehler. Analysis of anti‐proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi‐receptor tyrosine kinase pathways. International Journal of Cancer 2010; 127(5): 1197 doi: 10.1002/ijc.25137
|
| 6 |
Enrique Carrillo de Santa Pau, Fernando Carrillo Arias, Enrique Caso Peláez, Gemma María Muñoz Molina, Ignacio Sánchez Hernández, Ignacio Muguruza Trueba, Ramón Moreno Balsalobre, Silvia Sacristán López, Alejandro Gómez Pinillos, María del Val Toledo Lobo. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009; 115(8): 1701 doi: 10.1002/cncr.24193
|
| 7 |
Michael S. Hoetker, Ralf Kiesslich, Mustafa Diken, Markus Moehler, Peter R. Galle, Yanqing Li, Martin Goetz. Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. Gastrointestinal Endoscopy 2012; 76(3): 612 doi: 10.1016/j.gie.2012.05.013
|
| 8 |
Omar Abdel-Rahman. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations. Tumor Biology 2015; 36(1): 21 doi: 10.1007/s13277-014-2797-9
|
| 9 |
K.-W. Lee, S. R. Park, D.-Y. Oh, Y.-I. Park, R. Khosravan, X. Lin, S.-Y. Lee, E.-J. Roh, O. Valota, M. J. Lechuga, Y.-J. Bang. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Investigational New Drugs 2013; 31(6): 1547 doi: 10.1007/s10637-013-0032-y
|
| 10 |
Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs 2011; 29(6): 1449 doi: 10.1007/s10637-010-9438-y
|
| 11 |
C. Gómez-Martín, R. Salazar, C. Montagut, M. Gil-Martín, J. A. Núñez, M. Puig, X. Lin, R. Khosravan, J. M. Tursi, M. J. Lechuga, J. Bellmunt. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Investigational New Drugs 2013; 31(2): 390 doi: 10.1007/s10637-012-9830-x
|
| 12 |
Fabiana G. Curea, Mohamed Hebbar, Silvia M. Ilie, Xenia E. Bacinschi, Oana G. Trifanescu, Inga Botnariuc, Rodica M. Anghel. Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals 2017; 32(10): 351 doi: 10.1089/cbr.2017.2249
|
| 13 |
Akiko Kawano Nagatsuma, Masaki Aizawa, Takeshi Kuwata, Toshihiko Doi, Atsushi Ohtsu, Hirofumi Fujii, Atsushi Ochiai. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 2015; 18(2): 227 doi: 10.1007/s10120-014-0360-4
|
| 14 |
M. Moehler, A. Mueller, J.T. Hartmann, M.P. Ebert, S.E. Al-Batran, P. Reimer, M. Weihrauch, F. Lordick, T. Trarbach, S. Biesterfeld, M. Kabisch, D. Wachtlin, P.R. Galle. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. European Journal of Cancer 2011; 47(10): 1511 doi: 10.1016/j.ejca.2011.04.006
|
| 15 |
Felipe P. Mesquita, Emerson Lucena da Silva, Pedro F. N. Souza, Luina B. Lima, Jackson L. Amaral, William Zuercher, Louise M. Albuquerque, Silvia H. B. Rabenhorst, Caroline A. Moreira‐Nunes, Maria E. Amaral de Moraes, Raquel C. Montenegro. Kinase inhibitor screening reveals aurora‐a kinase is a potential therapeutic and prognostic biomarker of gastric cancer. Journal of Cellular Biochemistry 2021; 122(10): 1376 doi: 10.1002/jcb.30015
|
| 16 |
Carl C. Schimanski, Tim Zimmermann, Irene Schmidtmann, Ines Gockel, Hauke Lang, Peter R. Galle, Markus Moehler, Martin R. Berger. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRα in colorectal cancer. International Journal of Colorectal Disease 2010; 25(2): 181 doi: 10.1007/s00384-009-0843-7
|
| 17 |
M. Moehler, A. Mueller, T. Trarbach, F. Lordick, T. Seufferlein, S. Kubicka, M. Geißler, S. Schwarz, P.R. Galle, S. Kanzler. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of Oncology 2011; 22(6): 1358 doi: 10.1093/annonc/mdq591
|
| 18 |
Li Ping Yang, Lin Chen Fu, Hong Guo, Liang Xi Xie. Expression of Vascular Endothelial Growth Factor C Correlates with Lymphatic Vessel Density and Prognosis in Human Gastroesophageal Junction Carcinoma. Onkologie 2012; 35(3): 88 doi: 10.1159/000336807
|
| 19 |
Florian Lordick, Tobias Schulze, Dirk Jäger. The role of biologics in stomach cancer. Targeted Oncology 2008; 3(2): 71 doi: 10.1007/s11523-008-0078-5
|
| 20 |
Markus Moehler, Christian Frings, Annett Mueller, Ines Gockel, Carl C Schimanski, Stefan Biesterfeld, Peter R Galle, Martin H Holtmann. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World Journal of Gastroenterology 2008; 14(26): 4156-4167 doi: 10.3748/wjg.14.4156
|
| 21 |
Jennifer M. Davis, Elizabeth Hyjek, Aliya N. Husain, Le Shen, Jennifer Jones, Lucia A. Schuger. Lymphatic Endothelial Differentiation in Pulmonary Lymphangioleiomyomatosis Cells. Journal of Histochemistry & Cytochemistry 2013; 61(8): 580 doi: 10.1369/0022155413489311
|
| 22 |
George Zarkavelis, Epaminontas Samantas, Georgia-Angeliki Koliou, Kyriaki Papadopoulou, Davide Mauri, Gerasimos Aravantinos, Anna Batistatou, Elissavet Pazarli, Dimitrios Tryfonopoulos, Anna Tsipoura, Mattheos Bobos, Amanda Psyrri, Thomas Makatsoris, Constantina Petraki, Dimitrios Pectasides, George Fountzilas, George Pentheroudakis. AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. Acta Oncologica 2021; 60(6): 785 doi: 10.1080/0284186X.2021.1912822
|
| 23 |
Anna D Wagner, Markus Moehler. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Current Opinion in Oncology 2009; 21(4): 381 doi: 10.1097/CCO.0b013e32832c42e0
|
| 24 |
Carl C. Schimanski, Friederike Schlaegel, Mareike Jordan, Markus Moehler, George Sgourakis, Daniel G. Drescher, Peter R. Galle, Hauke Lang, Ines Gockel. VEGF‐D Correlates with Metastatic Disease in Gastric Cancer Patients Undergoing Surgery. World Journal of Surgery 2011; 35(5): 1010 doi: 10.1007/s00268-011-1041-7
|
| 25 |
Narikazu Boku, Kei Muro, Nozomu Machida, Satoshi Hashigaki, Nobuyuki Kimura, Mie Suzuki, Mariajose Lechuga, Yoshinori Miyata. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Investigational New Drugs 2014; 32(2): 261 doi: 10.1007/s10637-013-9948-5
|
| 26 |
D. Drescher, I. Gockel, M. Moehler, O. Lyros, M. R. Berger, S. Timm, P. R. Galle, T. Junginger, H. Lang, C. C. Schimanski. Chirurgisches Forum und DGAV Forum 2009. Deutsche Gesellschaft für Chirurgie 2009; 38: 131 doi: 10.1007/978-3-642-00625-8_50
|
| 27 |
Alessandra Decio, Giulia Taraboletti, Veronica Patton, Rachele Alzani, Patrizia Perego, Robert Fruscio, Juliane M. Jürgensmeier, Raffaella Giavazzi, Dorina Belotti. Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. The American Journal of Pathology 2014; 184(4): 1050 doi: 10.1016/j.ajpath.2013.12.030
|
| 28 |
Thomas Thomaidis, Annett Maderer, Salah-Eddin Al-Batran, Janis Kany, Claudia Pauligk, Kristina Steinmetz, Arno Schad, Ralf Hofheinz, Harald Schmalenberg, Nils Homann, Peter Robert Galle, Markus Moehler. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-476
|
| 29 |
Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, Peter C. Thuss-Patience, Joern Ruessel, Susanna Hegewisch-Becker, Hansjochen Wilke, Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, Florian Weißinger, Hans-Joachim Schmoll, Frank Kullmann, Ludwig Fischer von Weikersthal, Jens T. Siveke, Jens Weusmann, Stephan Kanzler, Carl Christoph Schimanski, Melanie Otte, Lukas Schollenberger, Jochem Koenig, Peter R. Galle. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2736-9
|